KP922

KP922 is a prodrug of dextroamphetamine (d-amphetamine) developed by KemPharm (now Zevra Therapeutics) using its proprietary Ligand Activated Therapy (LAT) technology. It is designed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The LAT technology involves the covalent attachment of a ligand to the active stimulant molecule, creating a new chemical entity that is pharmacologically inactive until it is metabolized in the body, typically in the gastrointestinal tract. This approach is intended to provide a controlled, extended-release profile of dextroamphetamine, potentially reducing the risk of abuse and providing more consistent therapeutic levels compared to traditional stimulant formulations. KP922 was part of a 2019 licensing agreement with Gurnet Point Capital and Corium, which granted them an option to further develop and commercialize the candidate.